Related Experiment Videos
Is 'chemo-fog'/'chemo-brain' caused by cancer chemotherapy?
R B Raffa1, P V Duong, J Finney
1Temple University School of Pharmacy, Philadelphia, PA 19140, USA. robert.raffa@temple.edu
Journal of Clinical Pharmacy and Therapeutics
|April 26, 2006
Summary
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Navigating the labyrinth: Phenotypes of IgG4-related disease.
Journal of postgraduate medicine·2025
Impact of pharmacist-initiated educational interventions on improving medication reconciliation practice in geriatric inpatients during hospital admission in Vietnam.
Journal of clinical pharmacy and therapeutics·2022
Evaluation of off-label anti-vascular endothelial growth factor and steroid implant medication uses in macular edema due to retinal vein occlusion in Turkey.
Journal of clinical pharmacy and therapeutics·2022
A descriptive analysis of pharmacological management of aggression and/or agitation in patients with traumatic brain injury in a Southwest Virginia inpatient population.
Journal of clinical pharmacy and therapeutics·2022
Effects of caregiver counselling on medication persistence and adherence in patients with dementia at a pharmacist-managed clinic: A pilot study.
Journal of clinical pharmacy and therapeutics·2022
The 50% and 95% effective doses of remimazolam tosilate with adjuvant sufentanil for sedation in patients with liver cirrhosis undergoing oesophagogastric varices screening endoscopy.
Journal of clinical pharmacy and therapeutics·2022
Tumour necrosis factor inhibitor combined with intravenous immunoglobulin and heparin for treatment of recurrent spontaneous abortion: A two-centre, retrospective, cohort study.
Journal of clinical pharmacy and therapeutics·2022
Quercetin-carboxymethyl chitosan‑hydrogen nanomicelles for the treatment of chemotherapy induced oral mucositis in mice.
International journal of biological macromolecules·2026
TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS <10.
Future oncology (London, England)·2026
The mechanism of polycystic ovarian syndrome induced by circadian rhythm disturbance and the therapeutic effect of melatonin.
Journal of clinical biochemistry and nutrition·2026